ArticleDiabetologia2016
Diabetes, prostate cancer screening and risk of low- and high-grade prostate cancer: an 11 year historical population follow-up study of more than 1 million men.
Article in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02072902 (Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.British journal of cancer · 2021Pooled it
- Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.British journal of cancer · 2018Trial
- Metabolic convergence of diabetes and prostate cancer: from dysglycemia to tumor microenvironment reprogramming.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Review
- Polygenic Risk Score Predicts Prostate Cancer Risk Independent of Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults.Journal of the National Cancer Institute · 2025Article
- Association Between Diabetes and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis of Observational Studies.The world journal of men's health · 2025Article
- Review
- A retrospective study of prostate-specific antigen and international prostate symptoms scores from participants at a men's health screening initiative in Trinidad.Journal of family medicine and primary care · 2024Article
- New findings on the effects of diabetes and anti-diabetic drugs on prostate cancer.American journal of cancer research · 2024Article
- Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.Frontiers in endocrinology · 2023Article
- Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer.Cancer causes & control : CCC · 2022Article
- Differences in the relationship between diabetes and prostate cancer among Black and White non-Hispanic men.Cancer causes & control : CCC · 2021Article
- Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.JNCI cancer spectrum · 2021Article
- Outcomes of prostate cancer screening among men using antidiabetic medication.Scientific reports · 2021Article
- Depression and prostate cancer risk: A Mendelian randomization study.Cancer medicine · 2020Article
- The association of diabetes with risk of prostate cancer defined by clinical and molecular features.British journal of cancer · 2020Article
- Diabetes and cancer: Epidemiological and biological links.World journal of diabetes · 2020Review
- Cancer Progress and Priorities: Prostate Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.JAMA network open · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisAn inverse association has consistently been shown between diabetes and prostate cancer incidence. We investigated whether lower prostate cancer incidence among men with diabetes is attributable to lower detection due to prostate cancer screening patterns.
methodsWe studied a population-based historical cohort of 1,034,074 Israeli men aged 21-90 years, without a previous history of cancer. The cohort was followed-up from 2002 to 2012, according to diabetes morbidity, for frequency of prostate-specific antigen (PSA) testing, mean PSA values and detection of prostate cancer, after adjustment for age, ethnic origin, socioeconomic status and PSA testing.
resultsIn January 2002, 74,756 men had prevalent diabetes. During the 11 year follow-up, 765,483 (74%) remained diabetes-free and 193,835 developed diabetes. Approximately 10% more PSA screening was performed in men with than without diabetes, but the rate of PSA positivity (>4 μg/l) was 20% lower in men with diabetes. PSA values were already significantly lower in men who developed diabetes than in those who did not, 3 years before diabetes diagnosis. Reduced prostate cancer risk was observed among men with incident diabetes only for low-moderate grade tumours (Gleason score 2-6: adjusted HR 0.83; 95% CI 0.77, 0.89). No association was observed for high-grade tumours (Gleason score 7-10: HR 0.99; 95% CI 0.88, 1.11). CONCLUSIONS/
interpretationOur findings suggest that diabetes comorbidity is a factor to be considered in prostate cancer screening strategies, and specifically in the interpretation of PSA levels. Furthermore, our demonstration of reduced incidence of low-moderate grade but not high-grade prostate cancer tumours among men with diabetes supports the possibility that low PSA levels, rather than lower tumour risk, explains the observed reduced incidence of prostate cancer in men with diabetes.
trial registrationClinicalTrials.gov NCT02072902.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.